As price pressure intensifies in crowded therapy areas, healthcare systems are increasingly reliant on the introduction of generics and biosimilars in order to reduce spending. In this research, we test if physicians’ price sensitivity is sufficient to drive cost reductions alone, or if payer-led controls and guidelines must be implemented to effect this change.
Assessing the economic case for Alzheimer’s disease policy prioritisation
The analysis has highlighted specific areas where more urgent action is needed, specifically: Accelerating diagnosing patients at scale; Supporting expansion...